Skip to Content

Posts tagged with "Business and Markets"

  • Business and Markets

    Drug Synthesis In Printed Reactors

    I’m still trying to get my bearings with this new paper from the Cronin group at Glasgow. What it proposes is a new style of API (active pharmaceutical ingredient) production. Instead of being done in bench- or process-scale lab glassware or in production-plant reactors, these syntheses take place in 3D-printed reactors, connected together in… Read More
  • Business and Markets

    Hospitals Making Drugs?

    This story from the New York Times got a lot of attention yesterday, and understandably so. It’s fundamentally about the shortage of some generic drugs, a problem that’s been with us for some years now in one form or another. My own belief is that much of this is a regulatory problem, and I note… Read More
  • Business and Markets

    Inside Scientific Information?

    Here’s a question that came up in the comments the other day, after I wrote about the recent publication suggesting possible immune-response problems with the Cas9 protein used in CRISPR. That paper sent the stocks of the major companies in the area down about 10% (well, mostly, and only after people had a weekend to… Read More
  • Biological News

    CRISPR and Axovant: What the Market Thinks

    Let’s go to the NASDAQ for some insight on a couple of recent biopharma stories. First off is Axovant, a company that’s interesting in a number of distressing ways. I last wrote about them here, after their Alzheimer’s candidate came up short in the clinic, which was a development that surprised no one who had… Read More
  • Business and Markets

  • Business and Markets

    ‘Tis Unfortunately the Season

    Update: this post came just a few days before Teva announced that they’re starting a 14,000-job cutback, to run over the next two years. The season indeed. Unfortunately, the Thanksgiving-to-Christmas season is a traditional one in the drug industry for layoffs and site closures. This is especially true for larger companies, who time these th… Read More
  • Business and Markets

    A Grim Future? Here Are the Numbers.

    Here’s a bracing look at the state of the pharma business, especially regarding R&D costs and return on investment. And let me warn you – it’s not a feel-good sort of article, but the figures are hard to refute. The author, Kelvin Stott, comes out swinging: Here I apply a far simpler, much more robust… Read More
  • Business and Markets

    Merck In London – A Hub, or Not?

    News comes today that Merck is going to put in a new research site in London. I’m not sure if anyone saw that coming – their previous UK research site is long gone, and seems now to be turning into housing developments. And I’m sure that the government is very happy to announce this sort… Read More
  • Business and Markets

    More Movements at the Top of GSK

    GlaxoSmithKline has been having more than its share of ups and downs over the last few years. In 2014, they moved a lot of assets out of oncology, as part of a general rearrangement into higher-volume lower-cost areas. That was a pretty bold move – give management credit for not being timid, at least – Read More
  • "Me Too" Drugs

    The Drug Project Landscape

    Here’s a new paper in Nature Reviews Drug Discovery that’s going to the trouble of matching specific disease indications with specific mechanisms in drug projects over the last 20 years (both the successful ones and the unsuccessful ones). The authors (from Vertex) used the Cortellis commercial database (with a good deal of filtering an… Read More
123...